This is a paid press release. Contact the press release distributor directly with any inquiries.

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Inc.

Mon, February 23, 2026 at 9:00 PM GMT+9 2 min read

In this article:

ARVN

-3.62%

Arvinas Inc.

NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) – Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences:

**TD Cowen 46th Annual Health Care Conference** on Tuesday, March 3. Management will participate in a fireside chat, available **here**, at 1:10 p.m. ET.

**Leerink Global Healthcare Conference** on Monday, March 9. Management will participate in a fireside chat, available **here**, at 4:20 p.m. ET.

**Barclays 28th Annual Global Healthcare Conference** on Tuesday, March 10. Management will participate in a fireside chat, available **here**, at 11:00 a.m. ET.

**2026 Jefferies Biotech on the Beach Summit** on Wednesday, March 11.

Replays of the fireside chats will be available on the Events and Presentations section of the Company’s website.

About Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

Terms and Privacy Policy

Privacy Dashboard

More Info